Market Brief — June 8, 2026

US equities closed mixed as strength in technology lifted the Nasdaq Composite (^IXIC) 0.9% and the S&P 500 (SPX) 0.3%, while the Dow Jones Industrial Average (DJIA) slipped 0.2%. In Europe, the FTSE 100 (UKX) edged up 0.1% but the CAC 40 (FRA40) fell 0.2% and the DAX (DAX) lost 0.6% as investors digested a 3.8% drop in German factory orders. In Asia, the Shanghai Composite (000001.SS) finished flat with a 0.0% move on the day.

Sector performance in the US was led by technology (VGT) up 1.7%, energy (XLE) up 1.1%, and consumer discretionary (XLY) up 0.5%, while utilities (XLU) fell 1.9%, real estate (VNQ) 1.4%, and basic materials (XLB) 1.3%. Among top gainers, Tango Therapeutics (TNGX) surged 53.0%, Galaxy Digital (GLXY) 21.4%, Cerebras Systems (CBRS) 18.3%, MARA Holdings (MARA) 11.9%, and Oscar Health (OSCR) 11.8%. On the downside, Brady (BRC) dropped 15.1%, Argan (AGX) 10.8%, Telekomunikasi Indonesia (TLK) 9.5%, Fervo Energy (FRVO) 8.8%, and Ensign Group (ENSG) 8.2%.

US policy expectations stayed hawkish as the Fed kept the federal funds rate at 3.50%–3.75%, prediction and futures markets assigned over 95% probability of no change at the June 16–17 FOMC while some pricing reflected odds of a 2026 rate hike, April CPI rose to 3.8% year over year from 3.3% with energy inflation at 17.9%, and May nonfarm payrolls added 172,000 jobs with unemployment at 4.3%. In other data, German factory orders fell 3.8% month over month in April versus a -1.2% consensus and a prior 4.5% gain, while India’s Q1 current account swung to a $7.1 billion surplus from a $15.5 billion deficit against a -$15 billion consensus. Commodity and expectations indicators were mixed as WTI crude traded around $91–$91.43 and Brent $94–$98 after OPEC+ approved a 188,000 barrel-per-day July quota increase and Iran–Israel tensions, while the NY Fed survey showed 1-year inflation expectations easing to 3.5% and 3- and 5-year expectations steady at 3.1% and 3.0%.

Chip-related momentum supported equities as Nvidia traded at $207.77 with a $1.30 daily gain, Micron and Marvell each climbed over 4%, and Cerebras advanced 3% to $207.54 after at least nine banks initiated coverage and Citigroup set a $340 12‐month target. Biotech exposure came under pressure as Zealand Pharma shares closed down 22.7% after survodutide data showed strong liver-fat reductions but a 19% discontinuation rate for gastrointestinal events versus 2.9% on placebo and around 25% dropouts at the 6 mg dose. Crypto and healthcare news also drew attention, with Bitcoin (BTC) rising as much as 3.8% to nearly $64,200 after Strategy Inc. disclosed a $101 million purchase, and Roche and Nurix agreeing to an up-to-$2.3 billion licensing and collaboration for BTK degrader bexobrutideg that includes a $700 million upfront payment and envisages a potential launch around 2030 if Phase III trials are positive. Cosmos Health completed an acquisition of strategic intellectual property and expanded its nanotechnology investment initiatives. Announced transactions included Quantum Space agreeing to go public via a merger with Inflection Point Acquisition Corp. VI, Galmed Pharmaceuticals planning to acquire Colospan, Arcline Investment Management moving to acquire Continental Aerospace Technologies, and Stark Power agreeing to buy Sagebrush Infrastructure Partners to secure a 5.6 GW U.S. data center pipeline. Further announced deals saw Orange acquire full ownership of MasOrange in Spain, TerraCap Management purchase about 71,000 square feet of industrial property in Boca Raton, SRx Health Solutions acquire 4.99% of Smartkem (SMTK), Freegame merge with PREP through its Freegame Diamond platform, and Eleven acquire Stella Networks to add automated network compliance for hospitality.